## Abstract In patients with prostate cancer who manifest disease progression during combined androgen blockade therapy, discontinuation of antiandrogen treatment might result in prostateβspecific antigen decline, often associated with clinical improvement. The response called antiandrogen withdraw
β¦ LIBER β¦
The antiandrogen withdrawal syndrome
β Scribed by Wirth, M. P. ;Froschermaier, S. E.
- Publisher
- Springer
- Year
- 1997
- Tongue
- English
- Weight
- 535 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0300-5623
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Molecular basis for the antiandrogen wit
β
Hiroshi Miyamoto; Mujib M. Rahman; Chawnshang Chang
π
Article
π
2003
π
John Wiley and Sons
π
English
β 204 KB
Antiandrogen with drawal syndrome
β
J. Breul; R. Paul
π
Article
π
1998
π
Springer
π
German
β 199 KB
The antiandrogen withdrawal syndrome. Ex
β
Eric J. Small; Sandy Srinivas
π
Article
π
1995
π
John Wiley and Sons
π
English
β 584 KB
Codon 877 Mutation in the Androgen Recep
β
Hiroyoshi Suzuki; Koichiro Akakura; Akira Komiya; Sara Aida; Susumu Akimoto; Jun
π
Article
π
1996
π
John Wiley and Sons
π
English
β 591 KB
The growth of prostate cancer is androgen responsive, and androgen receptor (AR) is thought to play an important role in the development of this cancer. Recently, some reports demonstrated that AR gene mutations were detected in human prostate cancer tissues. We have previously reported that one of
The alcohol withdrawal syndrome
β
Charles G. Brown
π
Article
π
1982
π
Elsevier Science
π
English
β 597 KB
Treatment for alcohol withdrawal syndrom
β
Monika E. Henschke; Ramola S. Abhyankar; Margaret L. Yarbrough; Yves-Jacques Piq
π
Article
π
1983
π
Elsevier Science
π
English
β 124 KB